Rare Disease Report

Myeloproliferative Neoplasms

Patients with myeloproliferative neoplasms (MPN) with essential thrombocythemia (ET) or polycythemia vera (PV) were found to benefit from hydroxyurea therapy. 
Males with myeloproliferative neoplasms (MPN) were found to have inferior survival compared to females in a well-defined, prospective, observational cohort.
Investigators in Denmark found that both current and ex-smokers have an increased risk of developing myeloproliferative neoplasms.
Mayo Clinic investigators found young patients with myeloproliferative neoplasms who are under age 40 are a steadily growing population and seem to have longer survival than their older counterparts.
Interferon‐α2 and ruxolitinib combination therapy shows promise in treating myeloproliferative neoplasms, according to recent preliminary findings.
Investigators have found that the higher the symptom burden, the greater the detrimental impact on work productivity and daily activity for patients with myeloproliferative neoplasms.
Investigators in Cincinnati have linked a gene with myelodysplastic syndromes, potentially offering the first step toward a new genetic therapy.
Pauline Funchain MD, explains how better understanding of genetics can help shape future treatments for rare cancers.
Relatives of individuals with certain types of blood cancer may harbor inherited genetic changes that could influence their risk of developing diseases that arise from myeloid cells.
Investigators find boys treated with alkylating agents or with hydroxyurea for sickle cell disease resulted in a significant reduction in spermatogonial cell counts, suggesting that these agents can affect fertility.
Copyright © RareDR 2013-2019 Rare Disease Communications. All Rights Reserved.